Skip to Content
MilliporeSigma

Key Documents

View All Documentation

O1014

Octreotide

≥98% (HPLC), Somatostatin receptor agonist,

Synonym(s):

SMS 201-995

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C49H66N10O10S2
CAS Number:
83150-76-9
Molecular Weight:
1019.24
UNSPSC Code:
12352200
PubChem Substance ID:
329818892
NACRES:
NA.32
MDL number:
MFCD00871400
Assay:
≥98% (HPLC)
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Octreotide, ≥98% (HPLC)

Quality Level

200

assay

≥98% (HPLC)

solubility

H2O: soluble

storage temp.

−20°C

SMILES string

C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

InChI

1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1

InChI key

DEQANNDTNATYII-OULOTJBUSA-N

Gene Information

human ... SSTR1(6751), SSTR2(6752), SSTR3(6753), SSTR4(6754), SSTR5(6755)

General description

Octreotide is a somatostatin analogue with D-Phe-Cys-Phe-D-Trp-Lys-ThrCys-Thr-OH amino acid sequence.

Biochem/physiol Actions

Octreotide is three times more potent than the native hormone in inhibiting the secretion of growth hormone glucagon and insulin in vivo. Octreotide regulates serum prolactin levels and resolves galactorrhea or (secondary) amenorrhea in acromegaly patients. Hence, this peptide can be considered as a potent therapeutic for acromegaly treatment.
Somatostatin analog that is 3-times more potent than the native hormone in inhibiting the secretion of growth hormone.

Other Notes

Lyophilized from 0.1% TFA in H2O

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
128K1395
078K1258
107K1654
047K1659
086K1180

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Octreotide as primary therapy for acromegaly.
Newman CB
The Journal of Clinical Endocrinology and Metabolism, 83(9), 3034-3040 (1998)
Anders Sundin
Best practice & research. Clinical gastroenterology, 26(6), 803-818 (2013-04-16)
Neuroendocrine tumours (NETs) comprise a heterogeneous group of neoplasms with very varying clinical expression. A functioning NET, for instance in the pancreas, may be very small and yet give rise to severe endocrine symptoms whereas a patient with a small
Odaly Toffoletto et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 30-31, 31-36 (2016-09-23)
To extend available dosing options in the treatment of growth hormone deficiency, a comparative pharmacokinetic and pharmacodynamic phase-1 clinical study involving subcutaneous administration of growth hormone was conducted. The test formulation (biosimilar recombinant human growth hormone; r-hGH; Somatotropin) and reference
View All Related Papers

Global Trade Item Number

SKUGTIN
O1014-1MG04061826153123
O1014-500UG04061832677552